Wall Street analysts predict that TAIWAN LIPOSOME/S (NASDAQ:TLC) will announce $590,000.00 in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for TAIWAN LIPOSOME/S’s earnings. The lowest sales estimate is $500,000.00 and the highest is $670,000.00. TAIWAN LIPOSOME/S posted sales of $500,000.00 in the same quarter last year, which suggests a positive year over year growth rate of 18%. The business is expected to report its next earnings report on Monday, November 25th.

On average, analysts expect that TAIWAN LIPOSOME/S will report full-year sales of $6.80 million for the current fiscal year, with estimates ranging from $6.50 million to $7.12 million. For the next fiscal year, analysts anticipate that the firm will report sales of $2.33 million, with estimates ranging from $2.14 million to $2.50 million. Zacks’ sales averages are an average based on a survey of analysts that follow TAIWAN LIPOSOME/S.

A number of brokerages have recently issued reports on TLC. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of TAIWAN LIPOSOME/S in a research report on Monday, May 20th. Robert W. Baird assumed coverage on shares of TAIWAN LIPOSOME/S in a report on Thursday, June 20th. They set an “outperform” rating on the stock. Finally, Zacks Investment Research lowered shares of TAIWAN LIPOSOME/S from a “buy” rating to a “hold” rating in a report on Saturday, July 13th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $9.50.

An institutional investor recently bought a new position in TAIWAN LIPOSOME/S stock. Millennium Management LLC purchased a new position in shares of TAIWAN LIPOSOME/S (NASDAQ:TLC) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 109,500 shares of the company’s stock, valued at approximately $602,000. Millennium Management LLC owned about 0.34% of TAIWAN LIPOSOME/S as of its most recent SEC filing. Hedge funds and other institutional investors own 2.94% of the company’s stock.

NASDAQ:TLC traded up $0.46 during trading hours on Monday, reaching $5.48. The company’s stock had a trading volume of 100 shares, compared to its average volume of 634. The stock has a market cap of $161.22 million and a P/E ratio of -11.66. TAIWAN LIPOSOME/S has a 12 month low of $5.00 and a 12 month high of $11.00. The company has a quick ratio of 2.69, a current ratio of 2.69 and a debt-to-equity ratio of 0.73. The firm has a 50 day simple moving average of $5.22.

TAIWAN LIPOSOME/S Company Profile

Taiwan Liposome Company, Ltd., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of nanomedicines that combine its proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ingredients (APIs). Its BioSeizer lipid formulation technology enables pharmacokinetic (PK) control and local sustained release of APIs at the site of disease or injury; and NanoX targeted delivery technology enables prolonged PK profiles and enhanced distribution of liposome-encapsulated APIs at the desired site.

Featured Story: Understanding Price to Earnings Ratio (PE)

Get a free copy of the Zacks research report on TAIWAN LIPOSOME/S (TLC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for TAIWAN LIPOSOME/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TAIWAN LIPOSOME/S and related companies with MarketBeat.com's FREE daily email newsletter.